BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 16, 2026
Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

NeoPharm Implements Plan To Hasten LEP Drug Development

Feb. 3, 2003
By Aaron Lorenzo

Texas Biotechnology Regaining Rights To PAH Drug From ICOS

Feb. 3, 2003
By Aaron Lorenzo

NeoPharm Implements Plan To Hasten LEP Drug Development

Feb. 3, 2003
By Aaron Lorenzo

FDA Response Letter Seen As Positive Sign For MedImmune

Jan. 31, 2003
By Aaron Lorenzo
A complete response letter from the FDA regarding FluMist has elicited a positive reaction at MedImmune Inc., which also reported record revenue as part of its fourth-quarter and year-end earnings. (BioWorld Today)
Read More

FDA Response Letter Seen As Positive Sign For MedImmune

Jan. 31, 2003
By Aaron Lorenzo
A complete response letter from the FDA regarding FluMist has elicited a positive reaction at MedImmune Inc., which also reported record revenue as part of its fourth-quarter and year-end earnings. (BioWorld Today)
Read More

AtheroGenics Brings In $45M Through 7.2M-Share Offering

Jan. 30, 2003
By Aaron Lorenzo

AtheroGenics Brings In $45M Through 7.2M-Share Offering

Jan. 30, 2003
By Aaron Lorenzo

GTx Partners VSV Technology With Wyeth In First Major Deal

Jan. 29, 2003
By Aaron Lorenzo
At first glance, any correlation between biotechnology and auto parts would likely go unnoticed. But such an indirect relationship is integral to GTx Inc., a five-year-old company developing products primarily to treat men's health disorders, in large part with funding from an auto parts scion. (BioWorld Today)
Read More

GTx Partners VSV Technology With Wyeth In First Major Deal

Jan. 29, 2003
By Aaron Lorenzo
At first glance, any correlation between biotechnology and auto parts would likely go unnoticed. But such an indirect relationship is integral to GTx Inc., a five-year-old company developing products primarily to treat men's health disorders, in large part with funding from an auto parts scion. (BioWorld Today)
Read More

Nastech Regains Rights To ED Product Following FTC Ruling

Jan. 28, 2003
By Aaron Lorenzo
Nastech Pharmaceutical Co. Inc. is regaining all rights to a sexual dysfunction product developed for the past year in partnership with Pharmacia Corp., a breakup of sorts brought on by government concerns over a merger between the latter and Pfizer Inc., the maker of Viagra. (BioWorld Today)
Read More
Previous 1 2 … 206 207 208 209 210 211 212 213 214 … 237 238 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 15, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Businesswoman pressing dollar sign on touchscreen

    JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

    BioWorld
    It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing